Covid cases, controls spread in China

Covid cases, controls spread in China


Covid cases and controls have increased in China this month. Pictured here on Oct. 27, 2022, is a neighborhood in Shanghai that’s been fenced in for Covid control.

Future Publishing | Future Publishing | Getty Images

BEIJING — Covid controls in China have tightened in the last two weeks after more cities reported virus outbreaks.

The restrictions on business and social activity affected 9.2% of China’s gross domestic product as of Thursday, up from 7% on Oct. 16, according to Nomura’s model.

“Since the 20th National Party Congress kicked off on 16 October, domestic Covid case numbers have been clearly on an upward trajectory,” the firm’s chief China economist Ting Lu and a team said in a report Thursday. “The national lockdown situation has been getting … significantly worse.”

For Thursday, mainland China reported 214 Covid cases with symptoms and 1,123 without. The infections were reported in well over 20 of China’s 31 province-level regions.

Among the many outbreaks nationwide, infections in the capital city forced Universal Beijing Resort to close temporarily starting Wednesday. It was unclear if the resort would re-open in time for Halloween weekend.

Apple supplier Foxconn said Tuesday its factory in Zhengzhou, China, was affected by a small Covid outbreak.

We're seeing weakening consumer sentiment in Europe and China: Unilever CEO

However, many of the recent case clusters and ensuing Covid controls have occurred in less economically prominent parts of the country, such as areas within Qinghai and Xinjiang in the northwest.

The Nomura report also pointed out that some localities have not directly announced lockdown measures, making it difficult to assess the impact.

Little change on Covid after China’s big meeting

Read more about China from CNBC Pro

Fourth-quarter growth calls



Source

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More
Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More